Sanofi shares rally after firm narrows focus on key drugs

PARIS (Reuters) – Shares in Sanofi (PA:) rose on Monday after the French drugmaker said it was discontinuing research in diabetes and cardiovascular diseases and would focus on treatments such as its eczema medicine Dupixent to grow sales.

The company, which also announced cost savings targets and a goal to boost margins, is due to set out in detail its strategic plans under new chief executive Paul Hudson on Tuesday in Cambridge, Massachusetts.

Sanofi shares were up 5% in early trading, at 86.01 euros ($94.80) each.

“We are encouraged that Sanofi is prioritizing Dupixent,” analysts at Credit Suisse (SIX:) said in a note. The treatment, recently approved in other therapeutic areas such as asthma, could reach over 10 billion euros in sales, Sanofi said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.